论文部分内容阅读
目的:观察吉西他滨加用奥沙利铂联合治疗老年晚期非小细胞肺癌(NSCLC)近期疗效和毒性反应。方法:60例老年晚期NSCLC接受治疗,方案为吉西他滨800～1000mg/m~2静滴30min,第1天,第8天,奥沙利铂130mg/m~2静滴2h第1天, 21天为1周期,化疗2周期后评价疗效。结果:60例患者累计完成176个周期,,其中CR1例(1.7%),PR 24例(40%),PD 20例(33.3%),总有效(PR+CR)25例(41.7%),临床收益率(CR+PR+NC)40例(66.7%),中位缓解期为6.5个月。不良反应主要为骨髓抑制及神经系毒性。Ⅲ～Ⅳ级白细胞减少9例(15%),Ⅲ～Ⅳ级血小板减少8例(13.3%);神经毒性发生率80%,均为轻度。结论:吉西他滨联合奥沙利铂治疗老年晚期非小细胞肺癌有效率高,不良反应可以耐受。
Objective: To observe the short-term curative effect and toxicity of gemcitabine combined with oxaliplatin in the treatment of senile advanced non-small cell lung cancer (NSCLC). Methods: 60 elderly patients with advanced NSCLC received gemcitabine 800 ~ 1000mg / m 2 intravenously for 30min. The first day, the eighth day, oxaliplatin 130mg / m 2 intravenous infusion 2h on the first day, 21 days 1 cycle, 2 cycles after chemotherapy to evaluate the efficacy. RESULTS: Sixty-six patients had completed 176 cycles, of which CR1 (1.7%), PR 24 (40%), PD 20 (33.3%) and total PR + CR were 25 (41.7% The clinical rate of return (CR + PR + NC) 40 cases (66.7%), the median remission was 6.5 months. Adverse reactions are mainly myelosuppression and neurotoxicity. Ⅲ ~ Ⅳ leukopenia in 9 cases (15%), Ⅲ ~ Ⅳ thrombocytopenia in 8 cases (13.3%); neurotoxicity was 80%, were mild. Conclusion: Gemcitabine combined with oxaliplatin is effective in treating elderly patients with advanced non-small cell lung cancer and can tolerate adverse reactions.